MIS-C Follow-Up Proves Challenging Across Pediatric Hospitals
March 11, 2021
(Medscape) – The discovery of any novel disease or condition means a steep learning curve as physicians must develop protocols for diagnosis, management, and follow-up on the fly in the midst of admitting and treating patients. Medical society task forces and committees often release interim guidance during the learning process, but each institution ultimately has to determine what works for them based on their resources, clinical experience, and patient population. But when the novel condition demands the involvement of multiple different specialties, the challenge of management grows even more complex — as does follow-up after patients are discharged. Such has been the story with multisystem inflammatory syndrome in children (MIS-C), a complication of COVID-19 that shares some features with Kawasaki disease.